|AtriClip® System Surpasses 34,000 Units Sold|
AtriClip is the most widely used device indicated for left atrial appendage management
The LAA is a muscular pouch attached to the heart’s left atrium. In patients with Afib and other cardiac arrhythmias, blood can pool and form clots in the appendage, which may then leave the heart and cause strokes. One study concluded that more than 90 percent of detected blood clots in patients with atrial fibrillation are formed in the LAA.1
Patients who suffer from Afib have a 500 percent greater risk of stroke,
compared with the general population.2 Afib-related strokes
are associated with higher morbidity and mortality than non-Afib related
strokes.3 More than 2.7 million people in
For years, heart surgeons would remove the LAA with a cut-and-sew method
during surgery, which required extra time on the heart-lung machine and
posed a risk of hemorrhaging. The engineering team at
In 2010, the AtriClip System was cleared for sale in
“The AtriClip device is quick to place and provides consistent occlusion
of the appendage with minimal risk of hemorrhage," said Dr.
In early 2014,
“This study demonstrates our commitment to developing compelling
solutions that improve patients’ lives and decrease the social and
economic burden of atrial fibrillation,” said
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that address activities, events or developments that AtriCure expects, believes or anticipates will or may occur in the future, such as earnings estimates (including projections and guidance), other predictions of financial performance, launches by AtriCure of new products and market acceptance of AtriCure’s products. Forward-looking statements are based on AtriCure’s experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond AtriCure’s control. These risks and uncertainties include the rate and degree of market acceptance of AtriCure’s products, AtriCure’s ability to develop and market new and enhanced products, the timing of and ability to obtain and maintain regulatory clearances and approvals for its products, the timing of and ability to obtain reimbursement of procedures utilizing AtriCure’s products, AtriCure’s ability to consummate acquisitions or, if consummated, to successfully integrate acquired businesses into AtriCure’s operations, AtriCure’s ability to recognize the benefits of acquisitions, including potential synergies and cost savings, failure of an acquisition or acquired company to achieve its plans and objectives generally, risk that proposed or consummated acquisitions may disrupt operations or pose difficulties in employee retention or otherwise affect financial or operating results, competition from existing and new products and procedures or AtriCure’s ability to effectively react to other risks and uncertainties described from time to time in AtriCure’s SEC filings, such as fluctuation of quarterly financial results, reliance on third party manufacturers and suppliers, litigation or other proceedings, government regulation and stock price volatility. AtriCure does not guarantee any forward-looking statement, and actual results may differ materially from those projected. AtriCure undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
1 Jeff S. Healey, MD,
2 Benjamin EJ, Chen PS, Bild DE, et al. Prevention of atrial
fibrillation: report from a national heart, lung, and blood institute
workshop. Circulation. 2009
3 Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 2005 Jun;36(6):1115-9.
5. Ailawadi G, Gerdisch MW, Harvey RL, Hooker RL, Damiano RJJ,